Merck & Co. Inc. Secures Exclusive Rights to Hengrui Pharma's Promising Cardiovascular Drug for Up to $1.8 Billion

Merck & Co. Inc. has signed an exclusive agreement with Hengrui Pharma for HRS-5346, a phase 2 cardiovascular drug, involving up to $1.8 billion in payments. The drug targets lipop...